Despite medical therapy, these individuals have not found relief because of their symptoms and experience regular physician and er visits or hospitalizations because often they are unable to eat or keep meals down and maintain proper nutrition, according to lead investigator Jiande Chen, Ph.D., of the University of Texas Medical Branch. These are very serious symptoms and could be life-threatening as the procedure options for these individuals have become limited and there are no effective medicines, stated Dr.The study, appearing this month in The Journal of Clinical Investigation, highlights a new probability for potential Alzheimer’s treatment: altering the brain’s use of lipids, a class of fat-soluble compounds which includes cholesterol. It’s getting clear that ABCA1 could be a good drug target for Alzheimer’s therapies, Holtzman says. There are known medications that can increase ABCA1 levels, and with some further advancement of this or related classes of medicines and extra insights into how ABCA1 slows down plaque deposition, there might be a way to create a new approach to Alzheimer’s treatment. Discovered in 2001, ABCA1 is a naturally occurring enzyme under study because of its potential to treat cardiovascular disease already. Lipids like cholesterol aren’t soluble, so to become transported through the bloodstream and into and out of cells and organs, they have to be connected with molecules referred to as apolipoproteins.